Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients

Table 2 Association between CTC status by AdnaTest or by CTC-specific signature and response to systemic therapy in breast cancer patients

		AdnaTest	AdnaTest+		AdnaTest-			5-gene panel	5-gene panel+		5-gene panel-
Variable	N	N (evaluable)	N	%	N	%	p-value	N (evaluable)	N	%	N	%	p-value
Pathologic response (M0)	20	17	5	29.4	12	70.6		20	13	65.0	7	35.0
Responder (pCR)	2	2	2	100	0	0	.0952^a,c	2	2	100	0	0	.5294^a,c
Non responder	16	13	3	23.1	10	76.9	.0952^a,c	16	10	62.5	6	37.5	.5294^a,c
Unknown	2	2	0	0	2	100		2	1	50	1	50
RECIST response (M+)	31	29	13	44.8	16	55.2		29	24	82.7	5	17.2
CR	1	1	0	0.0	1	100.0	.6668^a,c,d 1.0^a,c,e	1	0	0.0	1	100.0	.1304^a,c,d .0705^a,c,e
PR	16	14	8	57.1	6	42.9		15	11	73.3	4	26.7
SD	1	1	0	0.0	1	100.0		1	1	100.0	0	0.0
PD	7	7	3	42.9	4	57.1		7	7	100.0	0	0.0
Unknown	6	6	2	33.3	4	66.7		5	5	100.0	0	0.0

M0 patients with early-stage breast cancer, M+ patients with metastatic breast cancer, pCR pathologic complete response, CR complete response, PR partial response, SD stable disease, PD progressive disease, RECIST Response Evaluation Criteria in Solid Tumors
^a Fisher’s exact test;
^b Chi-square test;
^c “unknown” were excluded from the test
^d CR/PR vs SD/PD
^e CR vs PR/SD vs PD

ISSN: 1756-9966